|
[1]Wu, S.H.; Ryvarden, L.; Chang, T.T. Antrodia camphorata (niu-chang-chih), new combination of a medicinal fungus in Taiwan. Bot. Bull. Acad. Sin., 1997, 38, 273-275. [2]Chang, T.T.; Chou, W.N. Antrodia cinnamomea reconsidered and A. salmonea sp. nov. on Cunninghamia konishii in Taiwan. Bot. Bull. Acad. Sin., 2004, 45, 347-352. [3]Chang, C.Y.; Lue, M.Y.; Pan, T.M. Determination of Adenosine, Cordycepin and Ergosterol Contents in Cultivated Antrodia camphorata by HPLC Method. J. Food and Drug Anal., 2005, 13, 338-342. [4]Ao, Z.H.; Xu, Z.H.; Lu, Z.M.; Xu, H.Y.; Zhang, X.M.; Dou, W.F. Niuchangchih (Antrodia camphorata) and its potential in treating liver diseases. J. Ethnopharmacol., 2009, 121(2), 194-212. [5]Su, C.H. Health Guardian Angel: Antrodia camphorata, EKS Book Publishing Co., Taipei, 2002. [6]Chen, C.J.; Su, C.H.; Lan, M.H. Study on solid cultivation and bioactivity of Antrodia camphorata. Fung. Sci., 2001, 16, 65-72. [7]Shen, Y.C.; Wang, Y.H.; Chou, Y.C.; Chen, C.F.; Lin, L.C.; Chang, T.T.; Tien, J.H.; Chou, C.J. Evaluation of the anti-inflammatory activity of zhankuic acids isolated from the fruiting bodies of Antrodia camphorata. Planta Med., 2004, 70(4), 310-314. [8]Hseu, Y.C.; Wu, F.Y.; Wu, J.J.; Chen, J.Y.; Chang, W.H.; Lu, F.J.; Lai, Y.C.; Yang, H.L. Anti-inflammatory potential of Antrodia Camphorata through inhibition of iNOS, COX-2 and cytokines via the NF-kappaB pathway. Int.Immunopharmacol., 2005, 5(13-14), 1914-1925. [9]Liu, D.Z.; Liang, H.J.; Chen, C.H.; Su, C.H.; Lee, T.H.; Huang, C.T.; Hou, W.C.; Lin, S.Y.; Zhong, W.B.; Lin, P.J.; Hung, L.F.; Liang, Y.C. Comparative anti-inflammatory characterization of wild fruiting body, liquid-state fermentation, and solid-state culture of Taiwanofungus camphoratus in microglia and the mechanism of its action. J. Ethnopharmacol., 2007, 113(1), 45-53. [10]Huang, C.H.; Chang, Y.Y.; Liu, C.W.; Kang, W.Y.; Lin, Y.L.; Chang, H.C.; Chen, Y.C. Fruiting body of Niuchangchih (Antrodia camphorata) protects livers against chronic alcohol consumption damage. J. Agric. Food Chem., 2010, 58(6), 3859-3866. [11]Geethangili, M.; Tzeng, Y.M. Review of Pharmacological Effects of Antrodia camphorata and Its Bioactive Compounds. Evid. Based Complement Alternat. Med., 2011, pp 212641. doi:10.1093/ecam/ nep108, 2011. [12]Lu, Z.M.; Tao, W.Y.; Zou, X.L.; Fu, H.Z.; Ao, Z.H. Protective effects of mycelia of Antrodia camphorata and Armillariella tabescens in submerged culture against ethanol-induced hepatic toxicity in rats. J. Ethnopharmacol., 2007, 110(1), 160-164. [13]Hsiao, G.; Shen, M.Y.; Lin, K.H.; Lan, M.H.; Wu, L.Y.; Chou, D.S.; Lin, C.H.; Su, C.H.; Sheu, J.R. Antioxidative and hepatoprotective effects of Antrodia camphorata extract. J. Agric. Food Chem., 2003, 51(11), 3302-3308. [14]Song, T.Y.; Yen, G.C. Protective effects of fermented filtrate from Antrodia camphorata in submerged culture against CCl4-induced hepatic toxicity in rats. J. Agric. Food Chem., 2003, 51(6), 1571-1577. [15]Chen, C.H.; Yang, S.W.; Shen, Y.C. New steroid acids from Antrodia cinnamomea, a fungal parasite of Cinnamomum micranthum. J. Nat. Prod., 1995, 58(11), 1655-1661. [16]Cherng, I.H.; Wu, D.P.; Chiang, H.C. Triterpenoids from Antrodia cinnamomea. Phytochemistry, 1996, 41(41), 263-267. [17]Shen, Y.C., C.F. Chen, Y.H. Wang, T.T. Chang and C.J. Chou. Evaluation of the immuno-modulating activity of some active principles isolated from the fruiting bodies of Antrodia camphorata. Chin. Pharm. J. , 2003, 55, 313-318. [18]Chen, J.J.; Lin, W.J.; Liao, C.H.; Shieh, P.C. Anti-inflammatory benzenoids from Antrodia camphorata. J. Nat. Prod., 2007, 70(6), 989-992. [19]Shen, C.C.; Wang, Y.H.; Chang, T.T.; Lin, L.C.; Don, M.J.; Hou, Y.C.; Liou, K.T.; Chang, S.; Wang, W.Y.; Ko, H.C.; Shen, Y.C. Anti-inflammatory ergostanes from the basidiomata of Antrodia salmonea. Planta Med., 2007, 73(11), 1208-1213. [20]Male, K.B.; Rao, Y.K.; Tzeng, Y.M.; Montes, J.; Kamen, A.; Luong, J.H. Probing inhibitory effects of Antrodia camphorata isolates using insect cell-based impedance spectroscopy: inhibition vs chemical structure. Chem. Res. Toxicol., 2008, 21(11), 2127-2133. [21]Yeh, C.T.; Rao, Y.K.; Yao, C.J.; Yeh, C.F.; Li, C.H.; Chuang, S.E.; Luong, J.H.; Lai, G.M.; Tzeng, Y.M. Cytotoxic triterpenes from Antrodia camphorata and their mode of action in HT-29 human colon cancer cells. Cancer letters, 2009, 285(1), 73-79. [22]Chen, Y.C.; Liu, Y.L.; Li, F.Y.; Chang, C.I.; Wang, S.Y.; Lee, K.Y.; Li, S.L.; Chen, Y.P.; Jinn, T.R.; Tzen, J.T. Antcin A, a steroid-like compound from Antrodia camphorata, exerts anti-inflammatory effect via mimicking glucocorticoids. Acta Pharmacol. Sin., 2011, 32(7), 904-911. [23]Ji, X.Y.; Tan, B.K.; Zhu, Y.Z. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol. Sin., 2000, 21(12), 1089-1094. [24]Lu, Y.; Foo, L.Y. Polyphenolics of Salvia--a review. Phytochemistry, 2002, 59(2), 117-140. [25]Yokozawa, T.; Lee, T.W.; Oura, H.; Nonaka, G.; Nishioka, I. Effect of magnesium lithospermate B in rats with sodium-induced hypertension and renal failure. Nephron, 1992, 60(4), 460-465. [26]Fung, K.P.; Wu, J.; Zeng, L.H.; Wong, H.N.; Lee, C.M.; Hon, P.M.; Chang, H.M.; Wu, T.W. Lithospermic acid B as an antioxidant-based protector of cultured ventricular myocytes and aortic endothelial cells of rabbits. Life Sci., 1993, 53(12), 189-193. [27]Yokozawa, T.; Chung, H.Y.; Dong, E.; Oura, H. Confirmation that magnesium lithospermate B has a hydroxyl radical-scavenging action. Exp. Toxicol. Pathol., 1995, 47(5), 341-344. [28]Kasimu, R.; Tanaka, K.; Tezuka, Y.; Gong, Z.N.; Li, J.X.; Basnet, P.; Namba, T.; Kadota, S. Comparative study of seventeen Salvia plants: aldose reductase inhibitory activity of water and MeOH extracts and liquid chromatography-mass spectrometry (LC-MS) analysis of water extracts. Chem. Pharm. Bull., 1998, 46(3), 500-504. [29]Wu, X.J.; Wang, Y.P.; Wang, W.; Sun, W.K.; Xu, Y.M.; Xuan, L.J. Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B. Acta Pharmacol. Sin., 2000, 21(9), 855-858. [30]O, K.; Lynn, E.G.; Vazhappilly, R.; Au-Yeung, K.K.; Zhu, D.Y.; Siow, Y.L. Magnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation. Life Sci., 2001, 68(8), 903-912. [31]Tzen, J.T.; Jinn, T.R.; Chen, Y.C.; Li, F.Y.; Cheng, F.C.; Shi, L.S.; She, H.; Chen, B.C.; Hsieh, V.; Tu, M.L. Magnesium lithospermate B possesses inhibitory activity on Na+,K+-ATPase and neuroprotective effects against ischemic stroke. Acta Pharmacol. Sin., 2007, 28(5), 609-615. [32]Chen, Y.C.; Jinn, T.R.; Chung, T.Y.; Li, F.Y.; Fan, R.J.; Tzen, J.T. Magnesium lithospermate B extracted from Salvia miltiorrhiza elevates intracellular Ca(2+) level in SH-SY5Y cells. Acta Pharmacol. Sin., 2010, 31(8), 923-929. [33]Hinata, M.; Kimura, J. Forefront of Na+/Ca2+ exchanger studies: stoichiometry of cardiac Na+/Ca2+ exchanger; 3:1 or 4:1? J. Pharm. Sci., 2004, 96(1), 15-18. [34]Blaustein, M.P. The interrelationship between sodium and calcium fluxes across cell membranes. Rev. Physiol. Biochem. Pharmacol., 1974, 70, 33-82. [35]Bers, D.M.; Despa, S. Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts. J. Pharm. Sci., 2006, 100(5), 315-322. [36]Skou, J.C. The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim. Biophys. Acta, 1957, 23(2), 394-401. [37]Skou, J.C.; Esmann, M. The Na,K-ATPase. J. Bioenerg. Biomembr., 1992, 24(3), 249-261. [38]Lebovitz, R.M.; Takeyasu, K.; Fambrough, D.M. Molecular characterization and expression of the (Na+ + K+)-ATPase alpha-subunit in Drosophila melanogaster. EMBO J., 1989, 8(1), 193-202. [39]Fambrough, D.M.; Lemas, M.V.; Hamrick, M.; Emerick, M.; Renaud, K.J.; Inman, E.M.; Hwang, B.; Takeyasu, K. Analysis of subunit assembly of the Na-K-ATPase. Am. J. Physiol., 1994, 266(3 Pt 1), C579-589. [40]O''Brien, W.J.; Lingrel, J.B.; Wallick, E.T. Ouabain binding kinetics of the rat alpha two and alpha three isoforms of the sodium-potassium adenosine triphosphate. Archives Biochem. Biophys., 1994, 310(1), 32-39. [41]Morris, J.F.; Ismail-Beigi, F.; Butler, V.P., Jr.; Gati, I.; Lichtstein, D. Ouabain-sensitive Na+,K(+)-ATPase activity in toad brain. Comp. Biochem. Physiology, 1997, 118(3), 599-606. [42]Lingrel, J.B.; Arguello, J.M.; Van Huysse, J.; Kuntzweiler, T.A. Cation and cardiac glycoside binding sites of the Na,K-ATPase. Ann. N.Y. Acad. Sci., 1997, 834, 194-206. [43]Koenderink, J.B.; Hermsen, H.P.; Swarts, H.G.; Willems, P.H.; De Pont, J.J. High-affinity ouabain binding by a chimeric gastric H+,K+-ATPase containing transmembrane hairpins M3-M4 and M5-M6 of the alpha 1-subunit of rat Na+,K+-ATPase. Proc. Natl. Acad. Sci. USA, 2000, 97(21), 11209-11214. [44]Qiu, L.Y.; Koenderink, J.B.; Swarts, H.G.; Willems, P.H.; De Pont, J.J. Phe783, Thr797, and Asp804 in transmembrane hairpin M5-M6 of Na+,K+-ATPase play a key role in ouabain binding. J. Biol. Chem., 2003, 278(47), 47240-47244. [45]Qiu, L.Y.; Krieger, E.; Schaftenaar, G.; Swarts, H.G.; Willems, P.H.; De Pont, J.J.; Koenderink, J.B. Reconstruction of the complete ouabain-binding pocket of Na,K-ATPase in gastric H,K-ATPase by substitution of only seven amino acids. J. Biol. Chem., 2005, 280(37), 32349-32355. [46]Qiu, L.Y.; Swarts, H.G.; Tonk, E.C.; Willems, P.H.; Koenderink, J.B.; De Pont, J.J. Conversion of the low affinity ouabain-binding site of non-gastric H,K-ATPase into a high affinity binding site by substitution of only five amino acids. J. Biol. Chem., 2006, 281(19), 13533-13539. [47]Ogawa, H.; Shinoda, T.; Cornelius, F.; Toyoshima, C. Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. Proc. Natl. Acad. Sci. USA, 2009, 106(33), 13742-13747. [48]Shinoda, T.; Ogawa, H.; Cornelius, F.; Toyoshima, C. Crystal structure of the sodium-potassium pump at 2.4 A resolution. Nature, 2009, 459(7245), 446-450. [49]CP, M.; M, M.; A, S.F. A short review on cardiotonic steroids and their aminoguanidine analogues. Molecules, 2000, 5, 51-81. [50]Schonfeld, W.; Weiland, J.; Lindig, C.; Masnyk, M.; Kabat, M.M.; Kurek, A.; Wicha, J.; Repke, K.R. The lead structure in cardiac glycosides is 5 beta, 14 beta-androstane-3 beta 14-diol. Naunyn Schmiedebergs Arch. Pharmacol., 1985, 329(4), 414-426. [51]Lin, S.C.; Way, E.L. A high affinity Ca2+-ATPase in enriched nerve-ending plasma membranes. Brain Res., 1982, 235(2), 387-392. [52]Li-Saw-Hee, F.L.; Lip, G.Y. Digoxin revisited. QJM, 1998, 91(4), 259-264. [53]Ferrandi, M.; Barassi, P.; Molinari, I.; Torielli, L.; Tripodi, G.; Minotti, E.; Bianchi, G.; Ferrari, P. Ouabain antagonists as antihypertensive agents. Curr. Pharm. Design, 2005, 11(25), 3301-3305. [54]Micheletti, R.; Mattera, G.G.; Rocchetti, M.; Schiavone, A.; Loi, M.F.; Zaza, A.; Gagnol, R.J.; De Munari, S.; Melloni, P.; Carminati, P.; Bianchi, G.; Ferrari, P. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J. Pharmacol. Exp. Ther., 2002, 303(2), 592-600. [55]Micheletti, R.; Palazzo, F.; Barassi, P.; Giacalone, G.; Ferrandi, M.; Schiavone, A.; Moro, B.; Parodi, O.; Ferrari, P.; Bianchi, G. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am. J. Cardiol., 2007, 99(2A), 24A-32A. [56]Ghali, J.K.; Smith, W.B.; Torre-Amione, G.; Haynos, W.; Rayburn, B.K.; Amato, A.; Zhang, D.; Cowart, D.; Valentini, G.; Carminati, P.; Gheorghiade, M. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am. J. Cardiol., 2007, 99(2A), 47A-56A. [57]Gheorghiade, M.; Blair, J.E.; Filippatos, G.S.; Macarie, C.; Ruzyllo, W.; Korewicki, J.; Bubenek-Turconi, S.I.; Ceracchi, M.; Bianchetti, M.; Carminati, P.; Kremastinos, D.; Valentini, G.; Sabbah, H.N.; Investigators, H.-H. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. Am. J. Cardiol., 2008, 51(23), 2276-2285. [58]Shah, S.J.; Blair, J.E.; Filippatos, G.S.; Macarie, C.; Ruzyllo, W.; Korewicki, J.; Bubenek-Turconi, S.I.; Ceracchi, M.; Bianchetti, M.; Carminati, P.; Kremastinos, D.; Grzybowski, J.; Valentini, G.; Sabbah, H.N.; Gheorghiade, M.; Investigators, H.-H. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am. Heart J., 2009, 157(6), 1035-1041. [59]Gong, X.; Sucher, N.J. Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Phytomedicine, 2002, 9(5), 478-484. [60]Liang, H.; Chen, S.; Shen, S. Clinical observation on influence of chinese medicines for promoting blood circulation to remove blood stasis on FIB and DD in plasma of patients with cerebral thrombosis. J. Tradit. Chin. Med., 2002, 22(4), 256-259. [61]Yang, M.; Sun, J.; Lu, Z.; Chen, G.; Guan, S.; Liu, X.; Jiang, B.; Ye, M.; Guo, D.A. Phytochemical analysis of traditional Chinese medicine using liquid chromatography coupled with mass spectrometry. J. Chromatogr. A., 2009, 1216(11), 2045-2062. [62]Liu, X.X.; Wang, L.; Chen, X.Q.; Deng, X.T.; Cao, Y.; Wang, Q. Simultaneous quantification of both triterpenoid and steroidal saponins in various Yunnan Baiyao preparations using HPLC-UV and HPLC-MS. J.Sep. Sci., 2008, 31(22), 3834-3846. [63]Zhang, Q.; Ye, M. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). J. Chromatogr. A., 2009, 1216(11), 1954-1969. [64]Chen, R.J.; Chung, T.Y.; Li, F.Y.; Lin, N.H.; Tzen, J.T. Effect of sugar positions in ginsenosides and their inhibitory potency on Na+/K+-ATPase activity. Acta Pharmacol. Sin., 2009, 30(1), 61-69. [65]Chen, R.J.; Chung, T.Y.; Li, F.Y.; Yang, W.H.; Jinn, T.R.; Tzen, J.T. Steroid-like compounds in Chinese medicines promote blood circulation via inhibition of Na+/K+ -ATPase. Acta Pharmacol. Sin., 2010, 31(6), 696-702.
[1]Wu, S.H.; Ryvarden L., Chang, T.T. Antrodia camphorata (niu-chang-chih), new combination of a medicinal fungus in Taiwan. Bot. Bull. Acad. Sin., 1997, 38, 273-275. [2]Su, C.H.; Health Guardian Angel: Antrodia camphorata, EKS Book Publishing Co., Taipei, 2002. [3]Chen, C.J.; Su, C.H.; Lan, M.H. Study on solid cultivation and bioactivity of Antrodia camphorata. Fung. Sci., 2001, 16, 65-72. [4]Shen, Y.C.; Wang, Y.H.; Chou, Y.C.; Chen, C.F.; Lin, L.C.; Chang, T.T.; Tien, J.H.; Chou, C.J. Evaluation of the anti-inflammatory activity of zhankuic acids isolated from the fruiting bodies of Antrodia camphorata. Planta Med., 2004, 70(4), 310-314. [5]Hseu, Y.C.; Wu, F.Y.; Wu, J.J.; Chen, J.Y.; Chang, W.H.; Lu, F.J.; Lai, Y.C.; Yang, H.L. Anti-inflammatory potential of Antrodia Camphorata through inhibition of iNOS, COX-2 and cytokines via the NF-kappaB pathway. Int. Immunopharmacol., 2005, 5(13-14), 1914-1925. [6]Liu, D.Z.; Liang, H.J.; Chen, C.H.; Su, C.H.; Lee, T.H.; Huang, C.T.; Hou, W.C.; Lin, S.Y.; Zhong, W.B.; Lin, P.J.; Hung, L.F.; Liang, Y.C. Comparative anti-inflammatory characterization of wild fruiting body, liquid-state fermentation, and solid-state culture of Taiwanofungus camphoratus in microglia and the mechanism of its action. J. Ethnopharmacol., 2007, 113(1), 45-53. [7]Ao, Z.H.; Xu, Z.H.; Lu, Z.M.; Xu, H.Y.; Zhang, X.M.; Dou, W.F. Niuchangchih (Antrodia camphorata) and its potential in treating liver diseases. J. Ethnopharmacol., 2009, 121(2), 194-212. [8]Huang, C.H.; Chang, Y.Y.; Liu, C.W.; Kang, W.Y.; Lin, Y.L.; Chang, H.C.; Chen, Y.C. Fruiting body of Niuchangchih (Antrodia camphorata) protects livers against chronic alcohol consumption damage. J. Agric. Food Chem., 2010, 58(6), 3859-3866. [9]Geethangili, M.; Tzeng, Y.M. Review of Pharmacological Effects of Antrodia camphorata and Its Bioactive Compounds. Evid. Based Complement Alternat. Med., 2011, pp 212641. doi:10.1093/ecam/ nep108, 2011. [10]Liu, D.Z.; Liang, Y.C.; Lin, S.Y.; Lin, Y.S.; Wu, W.C.; Hou, W.C.; Su, C.H. Antihypertensive activities of a solid-state culture of Taiwanofungus camphoratus (Chang-chih) in spontaneously hypertensive rats. Biosci., Biotechnol., Biochem., 2007, 71(1), 23-30. [11]Wang, G.J.; Tseng, H.W.; Chou, C.J.; Tsai, T.H.; Chen, C.T.; Lu, M.K. The vasorelaxation of Antrodia camphorata mycelia: involvement of endothelial Ca(2+)-NO-cGMP pathway. Life Sci., 2003, 73(21), 2769-2783. [12]Chen, C.H.; Yang, S.W.; Shen, Y.C. New steroid acids from Antrodia cinnamomea, a fungal parasite of Cinnamomum micranthum. J. Nat. Prod., 1995, 58(11), 1655-1661. [13]Cherng, I.H.; Wu, D.P.; Chiang, H.C. Triterpenoids from Antrodia cinnamomea. Phytochemistry, 1996, 41(41), 263-267. [14]Shen, Y.C., C.F. Chen, Y.H. Wang, T.T. Chang and C.J. Chou. Evaluation of the immuno-modulating activity of some active principles isolated from the fruiting bodies of Antrodia camphorata. Chin. Pharm. J. , 2003, 55, 313-318. [15]Chen, J.J.; Lin, W.J.; Liao, C.H.; Shieh, P.C. Anti-inflammatory benzenoids from Antrodia camphorata. J. Nat. Prod., 2007, 70(6), 989-992. [16]Shen, C.C.; Wang, Y.H.; Chang, T.T.; Lin, L.C.; Don, M.J.; Hou, Y.C.; Liou, K.T.; Chang, S.; Wang, W.Y.; Ko, H.C.; Shen, Y.C. Anti-inflammatory ergostanes from the basidiomata of Antrodia salmonea. Planta Med., 2007, 73(11), 1208-1213. [17]Male, K.B.; Rao, Y.K.; Tzeng, Y.M.; Montes, J.; Kamen, A.; Luong, J.H. Probing inhibitory effects of Antrodia camphorata isolates using insect cell-based impedance spectroscopy: inhibition vs chemical structure. Chem. Res. Toxicol., 2008, 21(11), 2127-2133. [18]Yeh, C.T.; Rao, Y.K.; Yao, C.J.; Yeh, C.F.; Li, C.H.; Chuang, S.E.; Luong, J.H.; Lai, G.M.; Tzeng, Y.M. Cytotoxic triterpenes from Antrodia camphorata and their mode of action in HT-29 human colon cancer cells. Cancer lett., 2009, 285(1), 73-79. [19]Chen, Y.C.; Liu, Y.L.; Li, F.Y.; Chang, C.I.; Wang, S.Y.; Lee, K.Y.; Li, S.L.; Chen, Y.P.; Jinn, T.R.; Tzen, J.T. Antcin A, a steroid-like compound from Antrodia camphorata, exerts anti-inflammatory effect via mimicking glucocorticoids. Acta Pharmacol. Sin., 2011, 32(7), 904-911. [20]Nah, S.Y.; Park, H.J.; McCleskey, E.W. A trace component of ginseng that inhibits Ca2+ channels through a pertussis toxin-sensitive G protein. Proc. Natl. Acad. Sci.U.S.A., 1995, 92(19), 8739-8743. [21]Choi, S.; Kim, H.J.; Ko, Y.S.; Jeong, S.W.; Kim, Y.I.; Simonds, W.F.; Oh, J.W.; Nah, S.Y. G alpha(q/11) coupled to mammalian phospholipase C beta 3-like enzyme mediates the ginsenoside effect on Ca(2+)-activated Cl(-) current in the Xenopus oocyte. J. Biol. Chem., 2001, 276(52), 48797-48802. [22]Rhim, H.; Kim, H.; Lee, D.Y.; Oh, T.H.; Nah, S.Y. Ginseng and ginsenoside Rg3, a newly identified active ingredient of ginseng, modulate Ca2+ channel currents in rat sensory neurons. Eur. J. Pharmacol., 2002, 436(3), 151-158. [23]Zhu, S.; Zou, K.; Cai, S.; Meselhy, M.R.; Komatsu, K. Simultaneous determination of triterpene saponins in ginseng drugs by high-performance liquid chromatography. Chem. Pharm. Bull., 2004, 52(8), 995-998. [24]Chen, R.J.; Chung, T.Y.; Li, F.Y.; Lin, N.H.; Tzen, J.T. Effect of sugar positions in ginsenosides and their inhibitory potency on Na+/K+-ATPase activity. Acta Pharmacol. Sin., 2009, 30(1), 61-69. [25]Chen, Y.C.; Jinn, T.R.; Chung, T.Y.; Li, F.Y.; Fan, R.J.; Tzen, J.T. Magnesium lithospermate B extracted from Salvia miltiorrhiza elevates intracellular Ca(2+) level in SH-SY5Y cells. Acta Pharmacol. Sin., 2010, 31(8), 923-929. [26]Tzen, J.T.; Jinn, T.R.; Chen, Y.C.; Li, F.Y.; Cheng, F.C.; Shi, L.S.; She, H.; Chen, B.C.; Hsieh, V.; Tu, M.L. Magnesium lithospermate B possesses inhibitory activity on Na+,K+-ATPase and neuroprotective effects against ischemic stroke. Acta Pharmacol. Sin., 2007, 28(5), 609-615. [27]Ogawa, H.; Shinoda, T.; Cornelius, F.; Toyoshima, C. Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. Proc. Natl. Acad. Sci.U.S.A., 2009, 106(33), 13742-13747. [28]Miller, B.T.; Singh, R.P.; Klauda, J.B.; Hodoscek, M.; Brooks, B.R.; Woodcock, H.L., 3rd CHARMMing: a new, flexible web portal for CHARMM. J. Chem. Inf. Model., 2008, 48(9), 1920-1929. [29]Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Chem. Inf. Model., 2003, 21(4), 289-307. [30]Chen, R.J.; Chung, T.Y.; Li, F.Y.; Yang, W.H.; Jinn, T.R.; Tzen, J.T. Steroid-like compounds in Chinese medicines promote blood circulation via inhibition of Na+/K+ -ATPase. Acta Pharmacol. Sin., 2010, 31(6), 696-702. [31]Chen, R.J.; Jinn, T.R.; Chen, Y.C.; Chung, T.Y.; Yang, W.H.; Tzen, J.T. Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors. Acta Pharmacol. Sin., 2011, 32(2), 141-151.
[1]Fisch, C. William Withering: An account of the foxglove and some of its medical uses 1785-1985. J. Am. Coll. Cardiol, 1985, 5(5 Suppl A), 1A-2A. [2]Li-Saw-Hee, F.L.; Lip, G.Y. Digoxin revisited. QJM, 1998, 91(4), 259-264. [3]Kjeldsen, K.; Norgaard, A.; Gheorghiade, M. Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure. Cardiovasc. Res., 2002, 55(4), 710-713. [4]Prassas, I.; Diamandis, E.P. Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov., 2008, 7(11), 926-935. [5]Schonfeld, W.; Menke, K.H.; Schonfeld, R.; Repke, K.R. 5 Beta,14 beta-androstane-3 beta,14-diol binds to the digitalis receptor site on Na/K-ATPase. J. Enzyme Inhib., 1987, 2(1), 37-45. [6]Zhou, J. Bioactive glycosides from Chinese medicines. Mem. Inst. Oswaldo Cruz, 1991, 86 Suppl 2, 231-234. [7]Chen, R.J.; Chung, T.Y.; Li, F.Y.; Lin, N.H.; Tzen, J.T. Effect of sugar positions in ginsenosides and their inhibitory potency on Na+/K+-ATPase activity. Acta Pharmacol. Sin., 2009, 30(1), 61-69. [8]Chen, R.J.; Chung, T.Y.; Li, F.Y.; Yang, W.H.; Jinn, T.R.; Tzen, J.T. Steroid-like compounds in Chinese medicines promote blood circulation via inhibition of Na+/K+ -ATPase. Acta Pharmacol. Sin., 2010, 31(6), 696-702. [9]Repke, K.R.H.; Drug Discovery Today, Elsevier, Amsterdam, 1997, Vol. 2, pp.110-160. [10]Bayram, M.; De Luca, L.; Massie, M.B.; Gheorghiade, M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am. J. Cardiol., 2005, 96(6A), 47G-58G. [11]Micheletti, R.; Mattera, G.G.; Rocchetti, M.; Schiavone, A.; Loi, M.F.; Zaza, A.; Gagnol, R.J.; De Munari, S.; Melloni, P.; Carminati, P.; Bianchi, G.; Ferrari, P. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J. Pharmacol. Exp. Ther., 2002, 303(2), 592-600. [12]Micheletti, R.; Palazzo, F.; Barassi, P.; Giacalone, G.; Ferrandi, M.; Schiavone, A.; Moro, B.; Parodi, O.; Ferrari, P.; Bianchi, G. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am. J. Cardiol., 2007, 99(2A), 24A-32A. [13]Ji, X.Y.; Tan, B.K.; Zhu, Y.Z. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol. Sin., 2000, 21(12), 1089-1094. [14]Lu, Y.; Foo, L.Y. Polyphenolics of Salvia--a review. Phytochemistry, 2002, 59(2), 117-140. [15]Yokozawa, T.; Lee, T.W.; Oura, H.; Nonaka, G.; Nishioka, I. Effect of magnesium lithospermate B in rats with sodium-induced hypertension and renal failure. Nephron, 1992, 60(4), 460-465. [16]Fung, K.P.; Wu, J.; Zeng, L.H.; Wong, H.N.; Lee, C.M.; Hon, P.M.; Chang, H.M.; Wu, T.W. Lithospermic acid B as an antioxidant-based protector of cultured ventricular myocytes and aortic endothelial cells of rabbits. Life Sci., 1993, 53(12), PL189-193. [17]Yokozawa, T.; Chung, H.Y.; Dong, E.; Oura, H. Confirmation that magnesium lithospermate B has a hydroxyl radical-scavenging action. Exp. Toxicol. Pathol., 1995, 47(5), 341-344. [18]Kasimu, R.; Tanaka, K.; Tezuka, Y.; Gong, Z.N.; Li, J.X.; Basnet, P.; Namba, T.; Kadota, S. Comparative study of seventeen Salvia plants: aldose reductase inhibitory activity of water and MeOH extracts and liquid chromatography-mass spectrometry (LC-MS) analysis of water extracts. Chem. Pharmaceutical. Bull., 1998, 46(3), 500-504. [19]Wu, X.J.; Wang, Y.P.; Wang, W.; Sun, W.K.; Xu, Y.M.; Xuan, L.J. Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B. Acta Pharmacol. Sin., 2000, 21(9), 855-858. [20]O, K.; Lynn, E.G.; Vazhappilly, R.; Au-Yeung, K.K.; Zhu, D.Y.; Siow, Y.L. Magnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation. Life Sci., 2001, 68(8), 903-912. [21]Tzen, J.T.; Jinn, T.R.; Chen, Y.C.; Li, F.Y.; Cheng, F.C.; Shi, L.S.; She, H.; Chen, B.C.; Hsieh, V.; Tu, M.L. Magnesium lithospermate B possesses inhibitory activity on Na+,K+-ATPase and neuroprotective effects against ischemic stroke. Acta Pharmacol. Sin., 2007, 28(5), 609-615. [22]Chen, Y.C.; Jinn, T.R.; Chung, T.Y.; Li, F.Y.; Fan, R.J.; Tzen, J.T. Magnesium lithospermate B extracted from Salvia miltiorrhiza elevates intracellular Ca(2+) level in SH-SY5Y cells. Acta Pharmacol. Sin., 2010, 31(8), 923-929. [23]Chen, R.J.; Jinn, T.R.; Chen, Y.C.; Chung, T.Y.; Yang, W.H.; Tzen, J.T. Active ingredients in Chinese medicines promoting blood circulation as Na+/K+ -ATPase inhibitors. Acta Pharmacol. Sin., 2011, 32(2), 141-151. [24] Ogawa, H.; Shinoda, T.; Cornelius, F.; Toyoshima, C. Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. Proc. Natl. Acad. Sci. U.S.A., 2009, 106(33), 13742-13747. [25] Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Chem. Inf. Model., 2003, 21(4), 289-307. [26]Skou, J.C.; Esmann, M. The Na,K-ATPase. J. Bioenerg. Biomember., 1992, 24(3), 249-261. [27]Rose, A.M.; Valdes, R., Jr. Understanding the sodium pump and its relevance to disease. Clinical Chem., 1994, 40(9), 1674-1685. [28]Morth, J.P.; Pedersen, B.P.; Toustrup-Jensen, M.S.; Sorensen, T.L.; Petersen, J.; Andersen, J.P.; Vilsen, B.; Nissen, P. Crystal structure of the sodium-potassium pump. Nature, 2007, 450(7172), 1043-1049. [29]Shinoda, T.; Ogawa, H.; Cornelius, F.; Toyoshima, C. Crystal structure of the sodium-potassium pump at 2.4 A resolution. Nature, 2009, 459(7245), 446-450. [30]Schonfeld, W.; Weiland, J.; Lindig, C.; Masnyk, M.; Kabat, M.M.; Kurek, A.; Wicha, J.; Repke, K.R. The lead structure in cardiac glycosides is 5 beta, 14 beta-androstane-3 beta 14-diol. Naunyn-Schmiedeberg''s Arch. Pharmacol., 1985, 329(4), 414-426. [31]CP, M.; M, M.; A, S.F. A short review on cardiotonic steroids and their aminoguanidine analogues. Molecules, 2000, 5, 51-81. [32]Blaustein, M.P. The interrelationship between sodium and calcium fluxes across cell membranes. Rev. Physiol Bioch.P., 1974, 70, 33-82. [33]Ferrandi, M.; Barassi, P.; Molinari, I.; Torielli, L.; Tripodi, G.; Minotti, E.; Bianchi, G.; Ferrari, P. Ouabain antagonists as antihypertensive agents. Curr. Pharm. Design, 2005, 11(25), 3301-3305. [34]Lin, S.C.; Way, E.L. A high affinity Ca2+-ATPase in enriched nerve-ending plasma membranes. Brain Res., 1982, 235(2), 387-392. [35]Jiang, R.W.; Lau, K.M.; Hon, P.M.; Mak, T.C.; Woo, K.S.; Fung, K.P. Chemistry and biological activities of caffeic acid derivatives from Salvia miltiorrhiza. Curr. Med. Chem., 2005, 12(2), 237-246. [36]Tanaka, T.M., S.; Nonaka, G.; Nishioka, I.; Yokozawa, T.; Chung, H.Y.; Oura, Magnesium and ammonium-potassium lithospermates B, the active principles having a uremia-preventive effect from Salvia miltiorrhiza. Chem. Pharm. Bull., 1989, 37, 340-344. [37]Shigematsu, T.; Tajima, S.; Nishikawa, T.; Murad, S.; Pinnell, S.R.; Nishioka, I. Inhibition of collagen hydroxylation by lithospermic acid magnesium salt, a novel compound isolated from Salviae miltiorrhizae Radix. Biochim. Biophys. Acta, 1994, 1200(1), 79-83. [38]Lin, N.H.; Chung, T.Y.; Li, F.Y.; Chen, H.A.; Tzen, J.T. Enhancing the potency of lithospermate B for inhibiting Na/K-ATPase activity by forming transition metal ion complexes. Acta Pharmacol. Sin., 2013. [39]Kulikov, A.; Eva, A.; Kirch, U.; Boldyrev, A.; Scheiner-Bobis, G. Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim. Biophys. Acta, 2007, 1768(7), 1691-1702. [40]Tzen, J.T.; Chen, R.J.; Chung, T.Y.; Chen, Y.C.; Lin, N.H. Active compounds in Chinese herbs and medicinal animal products which promote blood circulation via inhibition of Na+, K+-ATPase. Chang Gung Med. J., 2010, 33(2), 126-136. [41]Annunziato, L.; New strategies in stroke intervention, Humana Press, New York, 2009. [42]Wang, J.K.; Portbury, S.; Thomas, M.B.; Barney, S.; Ricca, D.J.; Morris, D.L.; Warner, D.S.; Lo, D.C. Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc. Natl. Acad. Sci. U.S.A, 2006, 103(27), 10461-10466. [43]Petersen, M.; Simmonds, M.S. Rosmarinic acid. Phytochemistry, 2003, 62(2), 121-125.
|